DJ Hardman & Co Research: Arix Bioscience (ARIX): Hitting the jackpot
Hardman & Co Research
Hardman & Co Research: Arix Bioscience (ARIX): Hitting the jackpot
06-Nov-2020 / 12:10 GMT/BST
Hardman & Co Research: Hitting the jackpot
Arix Bioscience (ARIX) is a listed global venture capital (VC) company that
presents an opportunity for institutional and retail investors to participate
in the high risk-return profile of early-stage biotech investing. ARIX
minimises risk through a combination of an expert investment team and
portfolio diversification. Along with its 2020 interim results, management
provided the market with some aspirational targets for the next three years,
which would see the NAV double to ca.GBP500m. News that Merck & Co is to
acquire portfolio company, VelosBio, for $2.75bn cash, giving ARIX >12x
return on its investment, will help to smash these targets.
Please click on the link below for the full report:
https://www.hardmanandco.com/research/corporate-research/hitting-the-jackpot/
[1]
If you are interested in meeting the company, you can register your interest
by clicking on the above link
To contact us: Contact:
Hardman & Co Martin Hall mh@hardmanandco.com
35 New Broad Street
London
EC2M 1NH
+44 20 7194 7622
www.hardmanandco.com
Follow us on Twitter
@HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [2] to read the statement.
About Hardman & Co: For the past 25 years Hardman has been producing
specialist research designed to improve investors' understanding of
companies, sectors, industries and investment securities. Our analysts are
highly experienced in their sectors, and have often been highly rated by
professional investors for their knowledge. Our focus is to raise companies'
profiles across the UK and abroad with outstanding research, investor
engagement programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this is clearly
stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative
of Capital Markets Strategy Ltd and is authorised and regulated by the
Financial Conduct Authority; our FCA registration number is 600843. Hardman
Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment
community, market counterparties and sophisticated and high net worth
investors as defined in the rules of the regulatory bodies. It is not
intended to be made available to unsophisticated retail investors. Anyone who
is unsure of their categorisation should consult their professional advisors.
This research is neither an offer, nor a solicitation, to buy or sell any
security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
1146213 06-Nov-2020
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=37f86401c5228113ed60617aa31804bc&application_id=1146213&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=1146213&site_id=vwd&application_name=news
(END) Dow Jones Newswires
November 06, 2020 07:10 ET (12:10 GMT)
© 2020 Dow Jones News
